Bundamedik Tbk PT (BMHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bundamedik Tbk PT (BMHS) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp4.73 Billion ≈ $277.39K USD) by net assets (Rp2.14 Trillion ≈ $125.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bundamedik Tbk PT - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Bundamedik Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bundamedik Tbk PT for a breakdown of total debt and financial obligations.
Bundamedik Tbk PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bundamedik Tbk PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stel Holdings Limited
NSE:STEL
|
0.004x |
|
Bailador Technology Investments Ltd
AU:BTI
|
-0.039x |
|
Maeil Holdings Co. Ltd
KQ:005990
|
0.032x |
|
MAISON POMMERY & ASSOCIES
PA:POMRY
|
-0.070x |
|
ShareHope Medicine Co Ltd
TWO:8403
|
0.028x |
|
Bhagyanagar India Limited
NSE:BHAGYANGR
|
-0.386x |
|
Pantages Capital Acquisition Corporation.
NASDAQ:PGAC
|
-0.003x |
|
Helixmith Co. Ltd
KQ:084990
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Bundamedik Tbk PT (2018–2024)
The table below shows the annual cash flow conversion efficiency of Bundamedik Tbk PT from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see BMHS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp2.15 Trillion ≈ $125.85 Million |
Rp33.98 Billion ≈ $1.99 Million |
0.016x | -44.64% |
| 2023-12-31 | Rp1.80 Trillion ≈ $105.47 Million |
Rp51.44 Billion ≈ $3.01 Million |
0.029x | -78.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.96 Million |
Rp237.47 Billion ≈ $13.91 Million |
0.131x | -36.61% |
| 2021-12-31 | Rp1.69 Trillion ≈ $98.84 Million |
Rp349.44 Billion ≈ $20.48 Million |
0.207x | +14.24% |
| 2020-12-31 | Rp1.05 Trillion ≈ $61.51 Million |
Rp190.36 Billion ≈ $11.15 Million |
0.181x | +34.54% |
| 2019-12-31 | Rp665.59 Billion ≈ $39.00 Million |
Rp89.72 Billion ≈ $5.26 Million |
0.135x | +63.82% |
| 2018-12-31 | Rp532.23 Billion ≈ $31.19 Million |
Rp43.79 Billion ≈ $2.57 Million |
0.082x | -- |
About Bundamedik Tbk PT
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, medical tourism, and dental clinic services management consulting businesses. It al… Read more